New Report Available: Slovenia Pharmaceuticals & Healthcare Report Q1 2015

From: Fast Market Research, Inc.
Published: Wed Dec 10 2014

We have maintained our forecasts for Slovenia going into 2015. However, we caution that with the new coalition government in place, reform of the healthcare sector is imminent over the coming months in the attempt to bring the budget deficit down. As a result, going into 2015 and 2016 we anticipate that the focus will remain on local generic drugmakers, with limited opportunities for innovative multinational companies.

Headline Expenditure Projections

* Pharmaceuticals: EUR720mn (USD960mn) in 2013 to EUR700mn (USD940mn) in 2014; -2.2% in local currency terms and -1.3% in US dollar terms. Forecast unchanged from previous quarter.
* Healthcare: EUR3.1bn (USD4.1bn) in 2013 to EUR3.0bn (USD4.0bn) in 2014; -2.6% in local currency terms and -1.7% in US dollar terms. Forecast unchanged from previous quarter.

Full Report Details at

Risk/Reward Rating

Slovenia scores 50.4 out of a total of 100 in our Pharmaceutical Risk/Reward Index for Q115 - unchanged from the previous quarter. This places the country 11thin our index of 20 countries and below the average for the region, which is 51.0.

Key Trends & Developments

* In September 2014, in response to growing tensions between Western and Eastern Europe, Slovenian local industry players were reported to be in discussions with Indian pharmaceutical companies. Deep Kapuria, chairman of the Regional Committee on Central Europe at the Confederation of Indian Industry (CII) and chairman of Hi-Tech Group said: 'In high technology, India can gain from the R&D strengths of Slovenia. And Slovenian companies can work with Indian partners to expand in central Europe,' reports Business World.
* In the same month, Prime Minister Miro Cerar announced government plans to reform the healthcare system, alongside promises of fiscal responsibility and the privatisation of state-owned companies. This forms the new coalition government's strategy to pull Slovenia away from economic crisis.
* Exporters of end products to Russia, such as Krka,...

The Slovenia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Slovenia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Slovenian pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Slovenia to test other views - a key input for successful budgeting and strategic business planning in the Slovenian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Thailand Pharmaceuticals & Healthcare Report Q1 2015
- Kenya Pharmaceuticals & Healthcare Report Q1 2015
- Hong Kong Pharmaceuticals & Healthcare Report Q1 2015
- Croatia Pharmaceuticals & Healthcare Report Q1 2015
- Singapore Pharmaceuticals & Healthcare Report Q1 2015
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »